Currently viewing the tag: "FTC v. Actavis"

On Monday, February 22nd, 2016, the First Circuit, in In re: Loestrin 24 Fe Antitrust Litigation, aligned with the Third Circuit in ruling that non cash reverse payment agreements, designed to delay the release and marketing of competing generic drugs, are subject to traditional rule of reason antitrust scrutiny.

Generic manufactures often enter the market [...]

Continue Reading

The issue of reverse payment settlements (or pay-for-delay settlements) in pharmaceutical patent infringement suits could potentially work its ways back up to the Supreme Court. The Court recently settled a deeply divided circuit split over the legality of such settlements in FTC v. Actavis, 133 S.Ct. 2223 (2013). In Actavis, the Court held that [...]

Continue Reading

Pharmaceutical companies, the Federal Trade Commission, and antitrust and intellectual property attorneys waited with bated breath for the Supreme Court’s monumental decision on the legality of reverse-payment settlements, announced in FTC v. Actavis. On June 17, 2013, everyone got their answer… or did they?

What happened?

In March, this blog outlined [...]

Continue Reading